Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: A randomised clinical trial

Diabetologia

Volumn 56, Issue 7, 2013, Pages 1503-1511

  Charbonnel, B ^a   Steinberg, H ^b   Eymard, E ^b   Xu, L ^b   Thakkar, P ^b   Prabhu, V ^b   Davies, M J ^b   Engel, S S ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antihyperglycaemic agents; Glimepiride; HbA1c; Liraglutide; Metformin; Sitagliptin; Treatment intensification; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DELIVERY DEVICE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84878837962     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2905-1     Document Type: Article

References (15)

1. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577-1596
2. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012
3. Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
4. Mudaliar S, Henry RR (2012) The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia 55:1865-1868
5. Deacon CF, Mannucci E, Ahren B (2012) Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes - a review and meta analysis. Diabetes Obes Metabol 14:762-767
6. Pratley RE, Nauck M, Bailey T et al (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375:1447-1456
7. Bergenstal RM, Wysham C, Macconell L et al (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376:431-439
8. Novo Nordisk (2012) Product information. Victoza (liraglutide (rDNA) injection). 04/2012. Bagsvaerd, Denmark, Novo Nordisk A/S
9. Hodges JL, Lehmann EL (1956) The efficiency of some nonparametric competitors of the t-test. Ann Math Stat 27:324-335
10. Miettinen O, Nurminen M (1985) Comparative analysis of two rates. Stat Med 4:213-226
11. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
12. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metabol 9:733-745
13. Dibonaventura MD, Wagner JS, Girman CJ et al (2010) Multinational internet-based survey of patient preference for newer oral or injectable type 2 diabetes medication. Patient Prefer Adherence 4:397-406
14. Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC (2007) Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 78:254-258
15. Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R (2011) Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med 28:333-337